Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Advicenne SA (3MM) Stock Price & Analysis

3MM Stock Chart & Stats

€0.65-€0.01(-1.82%)
At close: 5:30 PM GMT+1
EUR 1EUR 1.5EUR 221 Jul8 Sep14 Sep12 Oct
Day’s Range
EUR 0.65 - EUR 0.67
52-Week Range
EUR 0.59 - EUR 2.20
Previous Close
EUR 0.66
Volume
0
Average Volume (3M)
2
Market Cap
EUR 9.42M
Enterprise Value
EUR 38.08M
Total Cash (Recent Filing)
EUR 1.55M
Total Debt (Recent Filing)
EUR 21.18M
Price to Earnings (P/E)
217.1
Beta
0.50
Next Earnings
Apr 01, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Rare-disease Specialization

Advicenne’s focus on rare kidney and metabolic diseases gives it a specialized commercial and development position in defined patient populations. Its marketed Sibnayal product provides an established platform from which the company can pursue adoption, reimbursement, and geographic expansion over the coming quarters.

Improving Gross Profitability

The shift to positive gross margin indicates that product economics improved at the gross-profit level, even though the company remains loss-making overall. If maintained alongside greater sales scale, this improvement could support better operating leverage and reduce the funding burden of commercial growth.

Partner-enabled Commercialization

Advicenne can monetize its therapies through both product sales and commercialization agreements, allowing partners to support access in selected geographies. This model may broaden the reach of its products and create royalty, milestone, or licensing income without relying exclusively on direct selling.

Bears Say

Persistent Unprofitability

Continued operating and net losses show that current revenue has not yet covered the company’s operating base. Without sustained sales growth or further margin improvement, ongoing losses could constrain investment in development and commercialization while increasing dependence on outside capital.

Stressed Balance Sheet

Negative equity across multiple years signals a fragile capital structure and materially limits financial flexibility. Sizable debt relative to assets can make it harder to absorb operating setbacks, negotiate additional funding, or allocate capital toward product expansion without further balance-sheet pressure.

Ongoing Cash Burn

Persistent negative operating and free cash flow means the business is not currently self-funding its operations. The deterioration in 2025 increases the likelihood that Advicenne will need external financing to sustain activities, creating additional execution and capital-raising pressure.

Advicenne SA News

3MM FAQ

What was Advicenne SA’s price range in the past 12 months?
Advicenne SA lowest stock price was €0.59 and its highest was €2.20 in the past 12 months.
What is Advicenne SA’s market cap?
Advicenne SA’s market cap is €9.42M.
When is Advicenne SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Advicenne SA’s earnings last quarter?
Advicenne SA released its earnings results on Sep 17, 2026. The company reported €0.32 earnings per share for the quarter.
Is Advicenne SA overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Advicenne SA pay dividends?
Advicenne SA does not currently pay dividends.
What is Advicenne SA’s EPS estimate?
Advicenne SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Advicenne SA have?
Advicenne SA has 14,609,619 shares outstanding.
What happened to Advicenne SA’s price movement after its last earnings report?
Advicenne SA reported an EPS of €0.32 in its last earnings report. Following the earnings report the stock price went up 2.329%.
Which hedge fund is a major shareholder of Advicenne SA?
Currently, no hedge funds are holding shares in DE:3MM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology